Characterization of brivanib pharmacokinetics and exposure-response (E-R): Relationship of fatigue in patients with advanced and metastatic solid tumors

被引：0
|
作者：
Wang, X.
Syed, S.
Masson, E.
Walters, I. B.
Roy, A.
机构：
[1] Bristol Myers Squibb, Lawrenceville, NJ USA
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Bristol Myers Squibb, Wallingford, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3095
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3095
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Assessment of futibatinib exposure-response (E-R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA)
    Hollebecque, A.
    Bridgewater, J. A.
    Meric-Bernstam, F.
    Goyal, L.
    Arkenau, H-T.
    Yamamiya, I.
    Yamashita, F.
    Li, K.
    Wacheck, V.
    Doi, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S378 - S379
  • [2] Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors
    Mekhail, Tarek
    Masson, Eric
    Fischer, Bruce S.
    Gong, Jiachang
    Iyer, Ramaswamy
    Gan, Jinping
    Pursley, Janice
    Patricia, Daniel
    Williams, Daphne
    Ganapathi, Ram
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (11) : 1962 - 1966
  • [3] Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML)
    Wang, X.
    Hochhaus, A.
    Kantarjian, H. M.
    Agrawal, S.
    Roy, A.
    Pfister, M.
    Chen, T.
    Bleickardt, E.
    Nicaise, C.
    Shah, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Population Pharmacokinetics and Exposure-Response Relationship of Zimberelimab in Chinese Patients with Advanced Tumors
    Yang, Fang
    Lu, Yongying
    Bai, Lihui
    Deng, Chenhui
    Liu, Zhen
    Sun, Zhihua
    Li, Li
    Wang, Shicong
    Zhou, Li
    Feng, Haifeng
    Yan, Shaoyu
    Zhu, Jiman
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (08): : 897 - 906
  • [5] Characterizing Exposure-Response (E-R) Relationship of Safety for Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Melanoma
    Wang, Xiaoning
    Feng, Yan
    Statkevich, Paul
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S37 - S38
  • [6] Ipilimumab Exposure-Response (E-R) Analysis of Overall Survival (OS) in Patients with Advanced Melanoma
    Vezina, Heather E.
    Feng, Yan
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S28 - S28
  • [7] Ribociclib (KISQALI®) Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analysis of Neutropenia
    Lu, Yasong
    Huang, Pai-Hsi
    Zieba, Renata
    Samant, Tanay S.
    Dhuria, Shyeilla
    Elmeliegy, Mohamed
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S120 - S120
  • [8] CHARACTERIZATION OF EXPOSURE-RESPONSE (E-R) RELATIONSHIP FOR NIVOLUMAB IN SUBJECTS WITH ADVANCED MELANOMA PROGRESSING POST ANTI-CTLA4.
    Wang, X.
    Bajaj, G.
    Feng, Y.
    Gupta, M.
    Agrawal, S.
    Yang, A.
    Park, J.
    Roy, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S42 - S43
  • [9] Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors
    Mercier, Francois
    Djebli, Nassim
    Gonzalez-Sales, Mario
    Jaminion, Felix
    Meneses-Lorente, Georgina
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (03) : 363 - 372
  • [10] Phase I study of food effects on pharmacokinetics of brivanib alaninate in patients with advanced or metastatic solid tumors
    Hurwitz, H.
    LoRusso, P.
    Shapiro, G. I.
    Wolanksi, A.
    Chemidlin, J.
    Masson, E.
    Syed, S.
    Kollia, G.
    Conlon, K.
    EJC SUPPLEMENTS, 2008, 6 (12): : 135 - 135
12345